Literature DB >> 29153879

Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics.

Qin Chen1, Guangxuan Liu2, Shuo Liu2, Hongyan Su2, Yue Wang2, Jingyu Li2, Cong Luo3.   

Abstract

The tumor microenvironment (TME) has profound impacts on cancer progression and remodeling of the TME has emerged as a strategy to facilitate cancer therapy. Recently, great progress in TME modulation has been made, especially with the rapid developments in nanomedicine. In this review we outline the latest advances in remodeling of the TME based on nanotherapeutics. First, novel strategies developed to modulate the tumor extracellular matrix (ECM) are discussed, including disruption, mimicking, and intervening in tumor ECM fabrication. Then, emerging tumor-associated fibroblast (TAF)-based nanotherapeutics are reviewed, including disruption and targeting of TAFs. Furthermore, recent developments in tumor vessel disruption and normalization are discussed. Finally, emerging approaches in response to tumor hypoxia are presented, with special emphasis on delivering oxygen, generating oxygen, and targeting tumor hypoxia.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  extracellular matrix; hypoxia; nanotherapeutics; remodel tumor microenvironment; tumor vessels; tumor-associated fibroblasts

Mesh:

Substances:

Year:  2017        PMID: 29153879     DOI: 10.1016/j.tips.2017.10.009

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  42 in total

1.  Mannan-binding lectin suppresses growth of hepatocellular carcinoma by regulating hepatic stellate cell activation via the ERK/COX-2/PGE2 pathway.

Authors:  Junru Li; Huifang Li; Yu Yu; Yan Liu; Yunzhi Liu; Qiang Ma; Liyun Zhang; Xiao Lu; Xiang-Yang Wang; Zhengliang Chen; Daming Zuo; Jia Zhou
Journal:  Oncoimmunology       Date:  2018-10-10       Impact factor: 8.110

Review 2.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

Review 3.  Tackling TAMs for Cancer Immunotherapy: It's Nano Time.

Authors:  Yishun Yang; Jianfeng Guo; Leaf Huang
Journal:  Trends Pharmacol Sci       Date:  2020-10       Impact factor: 14.819

Review 4.  Membrane-core nanoparticles for cancer nanomedicine.

Authors:  Jianfeng Guo; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-22       Impact factor: 15.470

5.  A quantitative in silico platform for simulating cytotoxic and nanoparticle drug delivery to solid tumours.

Authors:  Peter A Wijeratne; Vasileios Vavourakis
Journal:  Interface Focus       Date:  2019-04-19       Impact factor: 3.906

6.  A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells.

Authors:  Wanbin Yang; Xiuli Gong; Xiulian Wang; Chao Huang
Journal:  Invest New Drugs       Date:  2018-11-29       Impact factor: 3.850

7.  Difference of TGF-β/Smads signaling pathway in epithelial-mesenchymal transition of normal colonic epithelial cells induced by tumor-associated fibroblasts and colon cancer cells.

Authors:  Xiu-Lian Wang; Chao Huang
Journal:  Mol Biol Rep       Date:  2019-03-05       Impact factor: 2.316

8.  Targeting lung cancer stem cells using combination of Tel and Docetaxel liposomes in 3D cultures and tumor xenografts.

Authors:  Peggy Arthur; Nilkumar Patel; Sunil Kumar Surapaneni; Arindam Mondal; Aragaw Gebeyehu; Arvind Bagde; Shallu Kutlehria; Ebony Nottingham; Mandip Singh
Journal:  Toxicol Appl Pharmacol       Date:  2020-06-12       Impact factor: 4.219

Review 9.  Extracellular Matrix: Emerging Roles and Potential Therapeutic Targets for Breast Cancer.

Authors:  Yunchun Zhao; Xiaoling Zheng; Yongquan Zheng; Yue Chen; Weidong Fei; Fengmei Wang; Caihong Zheng
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

10.  Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.

Authors:  Sunil Kumar Surapaneni; Ebony Nottingham; Arindam Mondal; Nilkumar Patel; Peggy Arthur; Aragaw Gebeyehu; Anil Kumar Kalvala; Arun K Rishi; Mandip Singh
Journal:  Anticancer Res       Date:  2021-09-01       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.